Ana P Ortiz, Sandra I García-Camacho1, Jeslie M Ramos-Cartagena2, Vivian Colón-López, Lianeris M Estremera-Rodríguez3, Kyara M Berríos-Toledo3, Josefina Romaguera4. 1. University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico. 2. University of Puerto Rico/MD Anderson Cancer Center Partnership for Excellence in Cancer Research Program, San Juan, Puerto Rico. 3. Department of Biostatistics and Epidemiology, Graduate School of Public Health, University of Puerto Rico, San Juan, Puerto Rico. 4. Department of Obstetrics and Gynecology, School of Medicine, University of Puerto Rico.
Abstract
OBJECTIVE: Anal cancer screening has been recommended for women with lower genital tract neoplasia, lupus, Crohn disease, HIV, and/or organ transplantation recipients. This study described and compared knowledge, attitudes, and experiences related to anal cancer and anal cancer screening between women at high risk for anal cancer and their counterparts. METHODS: This is a cross-sectional study within colposcopy and gynecology oncology clinics in Puerto Rico; 278 women 21 years or older and with prior diagnosis of gynecological neoplasia completed an interviewer-administered questionnaire. Women were categorized according to their medical history as being high risk or non-high risk for anal cancer. The high-risk group included women with a history of lower genital tract neoplasia, lupus, Crohn disease, HIV, and/or organ transplantation. RESULTS: Overall, 40.7% of the study population were at high risk for developing anal cancer. History of anal cancer screening was low among high-risk and non-high-risk women (11.5% vs 5.6%, p > .05). Less than 1% of all women reported to have had a high-resolution anoscopy. Most women (87.6%) had little knowledge about anal Pap test but were willing to have one if their doctors recommended it (96.5%). No major differences in knowledge, attitudes, or screening history were observed between high-risk and non-high-risk women. CONCLUSIONS: Although experts do not recommend routine anal cancer screening for the general population, they do recommend it for women within certain high-risk groups. Study findings highlight the importance of increasing education and awareness of anal cancer among high-risk patients and physicians, to promote better preventive methods, achieve early detection, and improve disease outcomes.
OBJECTIVE: Anal cancer screening has been recommended for women with lower genital tract neoplasia, lupus, Crohn disease, HIV, and/or organ transplantation recipients. This study described and compared knowledge, attitudes, and experiences related to anal cancer and anal cancer screening between women at high risk for anal cancer and their counterparts. METHODS: This is a cross-sectional study within colposcopy and gynecology oncology clinics in Puerto Rico; 278 women 21 years or older and with prior diagnosis of gynecological neoplasia completed an interviewer-administered questionnaire. Women were categorized according to their medical history as being high risk or non-high risk for anal cancer. The high-risk group included women with a history of lower genital tract neoplasia, lupus, Crohn disease, HIV, and/or organ transplantation. RESULTS: Overall, 40.7% of the study population were at high risk for developing anal cancer. History of anal cancer screening was low among high-risk and non-high-risk women (11.5% vs 5.6%, p > .05). Less than 1% of all women reported to have had a high-resolution anoscopy. Most women (87.6%) had little knowledge about anal Pap test but were willing to have one if their doctors recommended it (96.5%). No major differences in knowledge, attitudes, or screening history were observed between high-risk and non-high-risk women. CONCLUSIONS: Although experts do not recommend routine anal cancer screening for the general population, they do recommend it for women within certain high-risk groups. Study findings highlight the importance of increasing education and awareness of anal cancer among high-risk patients and physicians, to promote better preventive methods, achieve early detection, and improve disease outcomes.
Authors: Vivian Colón-López; Meredith S Shiels; Mark Machin; Ana P Ortiz; Howard Strickler; Philip E Castle; Ruth M Pfeiffer; Eric A Engels Journal: J Clin Oncol Date: 2017-11-15 Impact factor: 44.544
Authors: Patricia L Judson; Elizabeth B Habermann; Nancy N Baxter; Sara B Durham; Beth A Virnig Journal: Obstet Gynecol Date: 2006-05 Impact factor: 7.661
Authors: Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky Journal: J Low Genit Tract Dis Date: 2015-07 Impact factor: 1.925
Authors: Vivian Colón-López; Ana Patricia Ortiz; Lizbeth Del Toro-Mejías; Michael Clatts; Greduvel Durán-Guzmán; Naydi Pérez; Maria DaCosta; Joel Palefsky Journal: P R Health Sci J Date: 2015-09 Impact factor: 0.705
Authors: Jason Ong; Marcus Chen; Meredith Temple-Smith; Sandra Walker; Jennifer Hoy; Ian Woolley; Andrew Grulich; Christopher Fairley Journal: J Med Screen Date: 2013-12 Impact factor: 2.136
Authors: Serena A Rodriguez; Robin T Higashi; Andrea C Betts; Cynthia Ortiz; Jasmin A Tiro; Amneris E Luque; Arti Barnes Journal: J Low Genit Tract Dis Date: 2021-01-01 Impact factor: 3.842
Authors: Vivian Colon-López; Valerie Quiñones-Avila; Lizbeth M Del Toro-Mejías; Keysha Reyes; Manuel E Rivera; Kathleen Nieves; María M Sánchez-Vazquez; Magaly Martínez-Ferrer; Ana P Ortiz Journal: BMC Oral Health Date: 2014-01-24 Impact factor: 2.757